Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 207, Issue 1, Pages -Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2012.05.012
Keywords
biological markers; endometrial hyperplasia; immunohistochemistry; progesterone receptors; progestin
Categories
Funding
- NICHD NIH HHS [T32 HD052462-05, 5 R01 HD44813-02, R01 HD044813, T32 HD052462] Funding Source: Medline
- NINR NIH HHS [1F31NR013092-01, F31 NR013092] Funding Source: Medline
Ask authors/readers for more resources
OBJECTIVE: We sought to identify biomarkers associated with progestin therapy resistance and persistence/progression of endometrial hyperplasia. STUDY DESIGN: We performed a nested case-control study among women with complex (n = 73) and atypical (n = 41) hyperplasia treated with oral progestin, followed up 2-6 months for persistence/progression. We evaluated index endometrial protein expression for progesterone receptor isoform A, progesterone receptor isoform B (PRB), PTEN, Pax-2, and Bcl-2. Odds ratios and 95% confidence intervals (CIs) were estimated. RESULTS: Among women with atypical hyperplasia, high PRB expression was associated with 90% decreased risk of persistence/progression (95% CI, 0.01-0.8). High expression of progesterone receptor A and PRB suggested decreased risk of persistence/progression (odds ratio, 0.1; 95% CI, 0.02-1.0). These findings were not observed among women with complex hyperplasia. No associations were found with PTEN, Pax-2, and Bcl-2 protein expression. CONCLUSION: PRB expression shows promise as a biomarker of progestin response. Further research is warranted to understand how PRB expression may guide treatment decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available